Previous 10 | Next 10 |
SAN FRANCISCO, CA / ACCESSWIRE / May 18, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is pursuing, through its licensing arrangements, the development of a small molecule drug ("SMD") for the treatment of colon cancer. SMD is defined as any organic comp...
SAN FRANCISCO, CA / ACCESSWIRE / May 12, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") has submitted its initial application to the NASDAQ to begin the process of moving the listing from the Pink Sheets to the Capital Markets Tier of the NASDAQ Exchange....
Oncology Pharma (ONPH) has entered into a licensing agreement with Regen BioPharma for a technology utilizing small molecules to activate immune checkpoints for the treatment of colon cancer.The program aims to identify small molecules that inhibit the NR2F6 nuclear receptor, which has b...
SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) ONPH has entered into a licensing agreement with Regen BioPharma, Inc. for a technology utilizing small molecules to activate immune checkpoints for the treatment of colon cancer. The program entails identi...
SAN FRANCISCO, CA / ACCESSWIRE / April 21, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is moving ahead with advancing its efforts with Ribera Solutions' Conect2Med platform with Oncology Pharma's exclusivity for oncology, including drug development, cl...
SAN FRANCISCO, CA / ACCESSWIRE / April 14, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) On April 7, 2021 Oncology Pharma, Inc. (the "Company") reported that it had been granted an exclusive worldwide license by Regen BioPharma, Inc. to develop and commercialize pancreatic cancer treatments ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Little-known penny stock Regen Biopharma (OTCMKTS: RGBP ) has soared 800% at the time of writing. That’s not a typo. Investors in RGBP stock have booked an 8-bagger in this stock today as the company anno...
Oncology Pharma ([[ONPH]] +10.0%) has signed a license agreement with Regen BioPharma for intellectual property pertaining to mRNA to be used in developing a therapy for treating pancreatic cancer.The license agreement expands the company's portfolio of intellectual property that it plan...
SAN FRANCISCO, CA / ACCESSWIRE / April 7, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) signed a license agreement with Regen BioPharma Inc. for intellectual property pertaining to mRNA to be used in developing a therapy for treating pancreatic cancer. This license agreement expands the Comp...
Oncology Pharma (ONPH) announces that it has provided the initial financing for the initiation of formal drug development and preclinical planning based on the proprietary nanoemulsion technology licensed from NanoSmart Pharmaceuticals.The licensed technology possesses proprietary technology ...
News, Short Squeeze, Breakout and More Instantly...
Oncology Pharma Inc Company Name:
ONPH Stock Symbol:
OTCMKTS Market:
SAN FRANCISCO, CA / ACCESSWIRE / July 12, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is furthering progress in discussions with investors and developing the financing model towards the next step of the development process with its Nanoemulsion drug de...
SAN FRANCISCO, CA / ACCESSWIRE / June 29, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to be reviewing the financing for taking the steps on moving forward with its development process of. the Nanoemulsuion Drug Delivery System. Many antican...
SAN FRANCISCO, CA / ACCESSWIRE / June 8, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased that the initial feasibility stage is complete and results have met the threshold to move forward. The formulation under development consisted of the activ...